Literature DB >> 10755515

Damage to porcine islets of Langerhans after exposure to human blood in vitro, or after intraportal transplantation to cynomologus monkeys: protective effects of sCR1 and heparin.

W Bennet1, B Sundberg, T Lundgren, A Tibell, C G Groth, A Richards, D J White, G Elgue, R Larsson, B Nilsson, O Korsgren.   

Abstract

BACKGROUND: Porcine islets offer an attractive alternative to human islets in clinical islet transplantation. The preferred method of islet transplantation is intra-portal injection into the liver. We have recently shown, both in vitro with human islets and in vivo with porcine islets, that islets exposed to allogeneic blood trigger an injurious inflammatory reaction characterized by activation of both coagulation and the complement systems. We have now tested whether a similar reaction is triggered when xenogeneic porcine islets are exposed to human blood in vitro and after intraportal transplantation into primates. Furthermore, we investigated the effect of inhibiting the complement and coagulation systems.
METHOD: Islets isolated from adult and fetal porcine pancreas were perfused with fresh human blood in surface heparinized PVC tubings for 5-60 min. Blood cell counts and parameters related to coagulation and the complement system were analyzed, and islets were retrieved after the perifusion was examined by immunohistochemical method. Heparin and soluble complement receptor 1 (sCR1; TP10, 100 microg/ml) were added to the system in some experiments. Furthermore, adult porcine islets were transplanted intraportally into untreated and sCR1- (40 mg/kg BW i.v.) treated cynomolgus monkeys, and plasma insulin concentration was monitored during 60 min after transplantation.
RESULTS: Porcine islets perifused with human blood triggered an immediate inflammatory reaction, characterized by a rapid consumption and activation of platelets, consumption of neutrophils and monocytes, activation of the coagulation and complement systems, and release of large amounts of insulin. Islet morphologic analysis revealed damaged islets embedded in clots and infiltrated with CD11+ leukocytes. C3a and C5b-9 was deposited on the islet surface, but human immunoglobulin was not. Complement inhibition with sCR1 reduced insulin release significantly. Intraportal islet transplantation into untreated cynomolgus monkeys resulted in a marked and rapid increase in plasma insulin concentration indicative of islet damage. Pretreatment of the monkeys with sCR1 resulted in significantly less insulin release than in untreated control monkeys.
CONCLUSION: Exposure of isolated xenogeneic islets of Langerhans to blood, both in vitro and in vivo, resulted in acute islet damage. Complement and platelets seem to have a central role in the reactions described. Strategies to efficiently inhibit these reactions will be crucial for clinical intraportal islet xenotransplantation to be successful.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10755515     DOI: 10.1097/00007890-200003150-00007

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  40 in total

Review 1.  Islet transplantation in the twenty-first century.

Authors:  Frank T Thomas; Anne Hutchings; Juan Contreras; Jianguo Wu; Xiao Ling Jiang; Devin Eckhoff; Judith M Thomas
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement.

Authors:  Stephen T Bartlett; James F Markmann; Paul Johnson; Olle Korsgren; Bernhard J Hering; David Scharp; Thomas W H Kay; Jonathan Bromberg; Jon S Odorico; Gordon C Weir; Nancy Bridges; Raja Kandaswamy; Peter Stock; Peter Friend; Mitsukazu Gotoh; David K C Cooper; Chung-Gyu Park; Phillip OʼConnell; Cherie Stabler; Shinichi Matsumoto; Barbara Ludwig; Pratik Choudhary; Boris Kovatchev; Michael R Rickels; Megan Sykes; Kathryn Wood; Kristy Kraemer; Albert Hwa; Edward Stanley; Camillo Ricordi; Mark Zimmerman; Julia Greenstein; Eduard Montanya; Timo Otonkoski
Journal:  Transplantation       Date:  2016-02       Impact factor: 4.939

3.  Neutrophilic granulocytes are the predominant cell type infiltrating pancreatic islets in contact with ABO-compatible blood.

Authors:  L Moberg; O Korsgren; B Nilsson
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

Review 4.  Cell transplantation for diabetes.

Authors:  Roy Calne
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

Review 5.  Innate immunity and heat shock response in islet transplantation.

Authors:  Y Lai; C Chen; T Linn
Journal:  Clin Exp Immunol       Date:  2009-02-04       Impact factor: 4.330

Review 6.  Pig-to-Primate Islet Xenotransplantation: Past, Present, and Future.

Authors:  Zhengzhao Liu; Wenbao Hu; Tian He; Yifan Dai; Hidetaka Hara; Rita Bottino; David K C Cooper; Zhiming Cai; Lisha Mou
Journal:  Cell Transplant       Date:  2017-02-03       Impact factor: 4.064

Review 7.  Macro- or microencapsulation of pig islets to cure type 1 diabetes.

Authors:  Denis Dufrane; Pierre Gianello
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

8.  Dissecting the instant blood-mediated inflammatory reaction in islet xenotransplantation.

Authors:  Masafumi Goto; Jenny Tjernberg; Denis Dufrane; Graciela Elgue; Daniel Brandhorst; Kristina Nilsson Ekdahl; Heidi Brandhorst; Lars Wennberg; Yoshimochi Kurokawa; Susumu Satomi; John D Lambris; Pierre Gianello; Olle Korsgren; Bo Nilsson
Journal:  Xenotransplantation       Date:  2008 Jul-Aug       Impact factor: 3.907

9.  Localized immune tolerance from FasL-functionalized PLG scaffolds.

Authors:  Michael Skoumal; Kyle B Woodward; Hong Zhao; Feng Wang; Esma S Yolcu; Ryan M Pearson; Kevin R Hughes; Andrés J García; Lonnie D Shea; Haval Shirwan
Journal:  Biomaterials       Date:  2018-11-13       Impact factor: 12.479

Review 10.  Pancreatic islet xenotransplantation: barriers and prospects.

Authors:  Gina R Rayat; Ronald G Gill
Journal:  Curr Diab Rep       Date:  2003-08       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.